ELSEVIER

Diabetes Research and Clinical Practice 55 (2002) 255–257

DIABETES RESEARCH AND CLINICAL PRACTICE

www.elsevier.com/locate/diabres

Author index of volume 55

Abdullaev, B., see King, H. **55**, 19
Agarwal, M.M., see Punnose, J. **55**, 29
Ahn, C.W., see Park, H.K. **55**, 151
Aller, R., see de Luis, D.A. **55**, 185
Al-Mousawi, M., see Johny, K.V. **55**, 123
Amemiya, S., see Mochizuki, M. **55**, 11
Arranz, M., see de Luis, D.A. **55**, 185
Asakawa, H., K. Tokunaga, F. Kawakami, Relationship of abdominal fat with metabolic disorders in diabetes mellitus patients **55**, 139
Aya, M., see Mochizuki, M. **55**, 11

Balkau, B., see Nakagami, T. **55**, 35
Banchuin, N., W. Boonyasrisawat, P. Pulsawat, S. Vannasaeng, C. Deerochanawong, S. Sriussadaporn, S. Ploybutr, T. Pasurakul, P.-t. Yenchitsomanus, No abnormalities of *reg*1α and *reg*1β gene associated with diabetes mellitus **55**, 105
Banchuin, N., W. Boonyasrisawat, S. Vannasaeng, T. Dharakul, P.-t. Yenchitsomanus, C. Deerochanawong, S. Ploybutr, S. Sriussadaporn, T. Pasurakul, Cell-mediated immune responses to GAD and β-casein in type 1 diabetes mellitus in Thailand **55**, 237
Bell, R.C., see Tudor-Locke, C.E. **55**, 191
Boonyasrisawat, W., see Banchuin, N. **55**, 105
Boonyasrisawat, W., see Banchuin, N. **55**, 237
Brian Haynes, R., see Gerstein, H.C. **55**, 209

Carstensen, B., see Nakagami, T. **55**, 35
Connelly, P.W., see Harris, S.B. **55**, 165
Costandi, J.N., see Johny, K.V. **55**, 123

Deerochanawong, C., see Banchuin, N. **55**, 105
Deerochanawong, C., see Banchuin, N. **55**, 237
de Luis, D.A., N. Fernandez, M. Arranz, R. Aller, O. Izaola, Total homocysteine and cognitive deterioration in people with type 2 diabetes **55**, 185
Devadas, K., see Punnose, J. **55**, 29
Dharakul, T., see Banchuin, N. **55**, 237
Djumaeva, S., see King, H. **55**, 19

Edenvall, H., see Sadauskaitė-Kuehne, V. **55**, 247
El Khadir, A., see Punnose, J. **55**, 29

Fernandez, N., see de Luis, D.A. **55**, 185
Fischer, S., see Hanefeld, M. **55**, 221
Fujita, K., see Shiba, T. **55**, 49

Gacic Dobo, M., see King, H. **55**, 19
Gerstein, H.C., K.E. Thorpe, D. Wayne Taylor, R. Brian Haynes, The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas—a randomized trial **55**, 209
Gittelsohn, J., see Harris, S.B. **55**, 165
Gupta, R.K., see Johny, K.V. **55**, 123

Haffner, S.M., see Hanefeld, M. **55**, 221
Hagura, R., see Shiba, T. **55**, 49
Hanefeld, M., S.M. Haffner, M. Menschikowski, C. Koehler, T. Temelkova-Kurktschiev, J. Wildbrett, S. Fischer, Different effects of acarbose and glibenclamide on proinsulin and insulin profiles in people with Type 2 diabetes **55**, 221
Hanley, A., see Harris, S.B. **55**, 165
Hara, H., see Ozaki, K. **55**, 159
Harris, S.B., B. Zinman, A. Hanley, J. Gittelsohn, R. Hegele, P.W. Connelly, B. Shah, J.E. Hux, The impact of diabetes on cardiovascular risk factors and outcomes in a native Canadian population **55**, 165
Harris, S.B., see Tudor-Locke, C.E. **55**, 191
Hashimoto, T., see Kanauchi, M. **55**, 229
Hegele, R., see Harris, S.B. **55**, 165
Hendra, T.J., see Reza, M. **55**, 201
Hintz, K.K., J. Ren, Prediabetic insulin resistance is not permissive to the development of cardiac resistance to insulin-like growth factor I in ventricular myocytes **55**, 89
Huang, Y., T. Ishizuka, A. Miura, K. Kajita, M. Ishizawa, M. Kimura, Y. Yamamoto, Y. Kawai, H. Morita, Y. Uno, K. Yasuda, Effect of 1α,25-dihydroxy vitamin D3 and vitamin E on insulin-induced glucose uptake in rat adipocytes **55**, 175

PII: S0168-8227(02)00011-6

Huh, K.B., see Park, H.K. **55**, 151
Hux, J.E., see Harris, S.B. **55**, 165

Ishihara, T., see Mochizuki, M. **55**, 11
Ishizawa, M., see Huang, Y. **55**, 175
Ishizuka, T., see Huang, Y. **55**, 175
Isogai, S., see Katayama, S. **55**, 113
Ito, C., see Kuzuya, T. **55**, 65
Iwamoto, Y., see Kuzuya, T. **55**, 65
Iwamoto, Y., see Nakagami, T. **55**, 35
Izaola, O., see de Luis, D.A. **55**, 185

Jašinskienė, E., see Sadauskaitė-Kuehne, V. **55**, 247
Johny, K.V., M.R.N. Nampoory, J.N. Costandi, R.K. Gupta, V.T. Ninan, M. Samhan, I. Muzairai, M. Al-Mousawi, High incidence of post-transplant diabetes mellitus in Kuwait **55**, 123

Kadowaki, T., see Kuzuya, T. **55**, 65
Kaino, Y., see Kohno, T. **55**, 1
Kajita, K., see Huang, Y. **55**, 175
Kanauchi, M., N. Tsujimoto, T. Hashimoto, Validation of simple indices to assess insulin sensitivity based on the oral glucose tolerance test in the Japanese population **55**, 229
Kanazawa, Y., see Kuzuya, T. **55**, 65
Kaneko, T., see Wang, Y. **55**, 61
Kasuga, A., see Mochizuki, M. **55**, 11
Katayama, S., R. Kikkawa, S. Isogai, N. Sasaki, N. Matsuura, N. Tajima, T. Urakami, Y. Uchigata, Y. Ohashi, Effect of captopril or imidapril on the progression of diabetic nephropathy in Japanese with type 1 diabetes mellitus: a randomized controlled study (JAPAN-IDDM) **55**, 113
Kato, K., see Mochizuki, M. **55**, 11
Kawai, Y., see Huang, Y. **55**, 175
Kawakami, F., see Asakawa, H. **55**, 139
Kida, K., see Kohno, T. **55**, 1
Kikkawa, R., see Katayama, S. **55**, 113
Kim, K.R., see Park, H.K. **55**, 151
Kim, S.J., see Park, H.K. **55**, 151
Kimura, M., see Huang, Y. **55**, 175
King, H., S. Djumaeva, B. Abdullaev, M. Gacic Dobo, Epidemiology of glucose intolerance and associated factors in Uzbekistan: a survey in Sirdaria province **55**, 19
Kobashiri, Y., see Kohno, T. **55**, 1
Kobayashi, K., see Mochizuki, M. **55**, 11
Kobayashi, K., see Mochizuki, M. **55**, 11
Kobayashi, M., see Kuzuya, T. **55**, 65
Koehler, C., see Hanefeld, M. **55**, 221
Kohno, N., see Ozaki, K. **55**, 159
Kohno, T., Y. Kobashiri, Y. Sugie, S. Takai, K. Watabe, Y. Kaino, K. Kida, Antibodies to food antigens in Japanese patients with type 1 diabetes mellitus **55**, 1
Kuzuya, T., S. Nakagawa, J. Satoh, Y. Kanazawa, Y. Iwamoto, M. Kobayashi, K. Nanjo, A. Sasaki, Y. Seino, C. Ito, K. Shima, K. Nonaka, T. Kadowaki, Report of the Committee on the classification and diagnostic criteria of diabetes mellitus **55**, 65

Lauzon, N., see Tudor-Locke, C.E. **55**, 191
Lavanya, A., see Shobhana, R. **55**, 45
Lee, G.T., see Park, H.K. **55**, 151
Lee, H.C., see Park, H.K. **55**, 151
Lim, S.K., see Park, H.K. **55**, 151
Ludvigsson, J., see Sadauskaitė-Kuehne, V. **55**, 247

Matsumoto, K., Y. Sera, H. Nakamura, Y. Ueki, S. Miyake, Serum concentrations of soluble adhesion molecules are related to degree of hyperglycemia and insulin resistance in patients with type 2 diabetes mellitus **55**, 131
Matsuura, N., see Katayama, S. **55**, 113
Menschikowski, M., see Hanefeld, M. **55**, 221
Mito, K., see Ozaki, K. **55**, 159
Miura, A., see Huang, Y. **55**, 175
Miyake, S., see Matsumoto, K. **55**, 131
Mochizuki, M., S. Amemiya, K. Kobayashi, K. Kobayashi, T. Ishihara, M. Aya, K. Kato, A. Kasuga, S. Nakazawa, The association of Ala45Thr polymorphism in *NeuroD* with child-onset Type 1a diabetes in Japanese **55**, 11
Mori, H., see Ozaki, K. **55**, 159
Morita, H., see Huang, Y. **55**, 175
Mugamer, I.T., see Punnose, J. **55**, 29
Muzairai, I., see Johny, K.V. **55**, 123
Myers, A.M., see Tudor-Locke, C.E. **55**, 191

Nakagami, T., Q. Qiao, J. Tuomilehto, B. Balkau, B. Carstensen, N. Tajima, Y. Iwamoto, The fasting plasma glucose cut-point predicting a diabetic 2-h OGTT glucose level depends on the phenotype **55**, 35
Nakagawa, S., see Kuzuya, T. **55**, 65
Nakamura, H., see Matsumoto, K. **55**, 131
Nakazawa, S., see Mochizuki, M. **55**, 11
Nampoory, M.R.N., see Johny, K.V. **55**, 123
Nanjo, K., see Kuzuya, T. **55**, 65
Ninan, V.T., see Johny, K.V. **55**, 123
Nonaka, K., see Kuzuya, T. **55**, 65

Ohashi, Y., see Katayama, S. **55**, 113
Okubo, M., see Ozaki, K. **55**, 159
Ozaki, K., M. Okubo, H. Mori, K. Mito, H. Hara, N. Kohno, Decreased insulin secretion and dyslipidemia coexist in subjects with impaired fasting glucose **55**, 159

Padaiga, Ž., see Sadauskaitė-Kuehne, V. **55**, 247
Padma, C., see Shobhana, R. **55**, 45
Park, H.K., C.W. Ahn, G.T. Lee, S.J. Kim, Y.D. Song, S.K. Lim, K.R. Kim, K.B. Huh, H.C. Lee, $(AC)_n$ polymorphism of aldose reductase gene and diabetic microvascular complications in type 2 diabetes mellitus **55**, 151
Pasurakul, T., see Banchuin, N. **55**, 105
Pasurakul, T., see Banchuin, N. **55**, 237
Ploybutr, S., see Banchuin, N. **55**, 105
Ploybutr, S., see Banchuin, N. **55**, 237
Ploybutr, S., see Vichayanrat, A. **55**, 99
Pulsawat, P., see Banchuin, N. **55**, 105

Punnose, J., M.M. Agarwal, A. El Khadir, K. Devadas, I.T. Mugamer, Childhood and adolescent diabetes mellitus in Arabs residing in the United Arab Emirates **55**, 29

Qiao, Q., see Nakagami, T. **55**, 35

Ramachandran, A., see Shobhana, R. **55**, 45
Rama Rao, P., see Shobhana, R. **55**, 45
Ren, J., see Hintz, K.K. **55**, 89
Reza, M., C.D. Taylor, K. Towse, J.D. Ward, T.J. Hendra, Insulin improves well-being for selected elderly type 2 diabetic subjects **55**, 201
Rodger, N.W., see Tudor-Locke, C.E. **55**, 191

Sadauskaitė-Kuehne, V., U. Samuelsson, E. Jašinskienė, Ž. Padaiga, B. Urbonaitė, H. Edenvall, J. Ludvigsson, Severity at onset of childhood type 1 diabetes in countries with high and low incidence of the condition **55**, 247
Samhan, M., see Johny, K.V. **55**, 123
Samuelsson, U., see Sadauskaitė-Kuehne, V. **55**, 247
Sasaki, A., see Kuzuya, T. **55**, 65
Sasaki, N., see Katayama, S. **55**, 113
Sato, A., see Wang, Y. **55**, 61
Satoh, J., see Kuzuya, T. **55**, 65
Sato, Y., see Shiba, T. **55**, 49
Seino, Y., see Kuzuya, T. **55**, 65
Sekihara, H., see Shiba, T. **55**, 49
Seki, U., see Shiba, T. **55**, 49
Sera, Y., see Matsumoto, K. **55**, 131
Shah, B., see Harris, S.B. **55**, 165
Shiba, T., T. Yamamoto, U. Seki, N. Utsugi, K. Fujita, Y. Sato, H. Terada, H. Sekihara, R. Hagura, Screening and follow-up of diabetic retinopathy using a new mosaic 9-field fundus photography system **55**, 49
Shima, K., see Kuzuya, T. **55**, 65
Shobhana, R., P. Rama Rao, A. Lavanya, R. Williams, C. Padma, V. Vijay, A. Ramachandran, Costs incurred by families having Type 1 diabetes in a developing country—a study from Southern India **55**, 45
Song, Y.D., see Park, H.K. **55**, 151
Sriussadaporn, S., see Banchuin, N. **55**, 105
Sriussadaporn, S., see Banchuin, N. **55**, 237
Sugie, Y., see Kohno, T. **55**, 1

Tajima, N., see Katayama, S. **55**, 113
Tajima, N., see Nakagami, T. **55**, 35
Takai, S., see Kohno, T. **55**, 1
Taylor, C.D., see Reza, M. **55**, 201
Temelkova-Kurktschiev, T., see Hanefeld, M. **55**, 221
Terada, H., see Shiba, T. **55**, 49
Thorpe, K.E., see Gerstein, H.C. **55**, 209
Tokunaga, K., see Asakawa, H. **55**, 139
Towse, K., see Reza, M. **55**, 201
Tsujimoto, N., see Kanauchi, M. **55**, 229
Tudor-Locke, C.E., R.C. Bell, A.M. Myers, S.B. Harris, N. Lauzon, N.W. Rodger, Pedometer-determined ambulatory activity in individuals with type 2 diabetes **55**, 191
Tunlakit, M., see Vichayanrat, A. **55**, 99
Tuomilehto, J., see Nakagami, T. **55**, 35

Uchigata, Y., see Katayama, S. **55**, 113
Ueki, Y., see Matsumoto, K. **55**, 131
Uno, Y., see Huang, Y. **55**, 175
Urakami, T., see Katayama, S. **55**, 113
Urbonaitė, B., see Sadauskaitė-Kuehne, V. **55**, 247
Utsugi, N., see Shiba, T. **55**, 49

Vannasaeng, S., see Banchuin, N. **55**, 105
Vannasaeng, S., see Banchuin, N. **55**, 237
Vichayanrat, A., S. Ploybutr, M. Tunlakit, P. Watanakejorn, Efficacy and safety of voglibose in comparison with acarbose in type 2 diabetic patients **55**, 99
Vijay, V., see Shobhana, R. **55**, 45

Wang, P.-Y., see Wang, Y. **55**, 61
Wang, Y., T. Kaneko, P.-Y. Wang, A. Sato, Decreased carbohydrate intake is more important than increased fat intake in the glucose intolerance by a low-carbohydrate/high-fat diet **55**, 61
Ward, J.D., see Reza, M. **55**, 201
Watabe, K., see Kohno, T. **55**, 1
Watanakejorn, P., see Vichayanrat, A. **55**, 99
Wayne Taylor, D., see Gerstein, H.C. **55**, 209
Wildbrett, J., see Hanefeld, M. **55**, 221
Williams, R., see Shobhana, R. **55**, 45

Yamamoto, T., see Shiba, T. **55**, 49
Yamamoto, Y., see Huang, Y. **55**, 175
Yasuda, K., see Huang, Y. **55**, 175
Yenchitsomanus, P.-t., see Banchuin, N. **55**, 105
Yenchitsomanus, P.-t., see Banchuin, N. **55**, 237

Zinman, B., see Harris, S.B. **55**, 165

ELSEVIER

Diabetes Research and Clinical Practice 55 (2002) 259–262

DIABETES RESEARCH AND CLINICAL PRACTICE

www.elsevier.com/locate/diabres

Subject index of volume 55

Acarbose; Glibenclamide; Insulin; Proinsulin; 24-h profiles **55**, 221

Acarbose; α-Glucosidase inhibitor; Voglibose; Postprandial hyperglycemia; Treatment of type 2 diabetes **55**, 99

Adipocytes; 1α,25-Dihydroxy vitamin D3; Vitamin E; Insulin; Glucose uptake; Protein kinase C **55**, 175

Aldose reductase gene polymorphism; Type 2 diabetes mellitus; Diabetic nephropathy; Diabetic retinopathy **55**, 151

Antibodies; Bovine serum albumin; Lactoglobulin; Ovalbumin; Type 1 diabetes mellitus **55**, 1

Arabs; Childhood diabetes mellitus; Middle East **55**, 29

Asian populations; Diagnostic criteria; Diabetes; Fasting glucose; Screening; Oral glucose tolerance test **55**, 35

Bovine serum albumin; Lactoglobulin; Ovalbumin; Antibodies; Type 1 diabetes mellitus **55**, 1

Captopril; Diabetes mellitus; Imidapril **55**, 113

Cardiovascular disease risk factors; Type 2 diabetes; Native Canadians **55**, 165

Carer stress; Elderly; Type 2 diabetes; Quality of life **55**, 201

β-Casein; GAD; Lymphoproliferation; Type 1 diabetes **55**, 237

Ca^{2+} transient; IGF-1; Insulin resistance; Ventricular myocyte; Cell shortening **55**, 89

Cell shortening; IGF-1; Insulin resistance; Ventricular myocyte; Ca^{2+} transient **55**, 89

Central Asia; Diabetes mellitus; Impaired glucose tolerance; Central obesity; Hypertension; Epidemiology; Uzbekistan **55**, 19

Central obesity; Diabetes mellitus; Impaired glucose tolerance; Hypertension; Epidemiology; Uzbekistan; Central Asia **55**, 19

Childhood diabetes mellitus; Middle East; Arabs **55**, 29

Childhood; Type 1 diabetes mellitus; Clinical manifestation; Onset; Ketoacidosis; Lithuania; Sweden **55**, 247

Classification; Diabetes mellitus; JDS; Diagnosis **55**, 65

Clinical manifestation; Type 1 diabetes mellitus; Onset; Ketoacidosis; Childhood; Lithuania; Sweden **55**, 247

Cognitive deterioration; Diabetes mellitus; Homocysteine **55**, 185

Cost burden; Type 1 diabetes; India; Health economics **55**, 45

Diabetes; Diagnostic criteria; Fasting glucose; Screening; Asian populations; Oral glucose tolerance test **55**, 35

Diabetes mellitus; Cognitive deterioration; Homocysteine **55**, 185

Diabetes mellitus; Imidapril; Captopril **55**, 113

Diabetes mellitus; Impaired glucose tolerance; Central obesity; Hypertension; Epidemiology; Uzbekistan; Central Asia **55**, 19

Diabetes mellitus; JDS; Diagnosis; Classification **55**, 65

Diabetes mellitus; Post-renal transplant; Outcome **55**, 123

PII: S0168-8227(02)00012-8

Diabetic nephropathy; Type 2 diabetes mellitus; Diabetic retinopathy; Aldose reductase gene polymorphism **55**, 151

Diabetic nephropathy; Visceral fat syndrome; Thrombin–antithrombin III complex; Fibrinogen; Gender **55**, 139

Diabetic retinopathy; Digital image; Screening; Telemedicine **55**, 49

Diabetic retinopathy; Type 2 diabetes mellitus; Diabetic nephropathy; Aldose reductase gene polymorphism **55**, 151

Diagnosis; Diabetes mellitus; JDS; Classification **55**, 65

Diagnostic criteria; Diabetes; Fasting glucose; Screening; Asian populations; Oral glucose tolerance test **55**, 35

Digital image; Diabetic retinopathy; Screening; Telemedicine **55**, 49

1α,25-Dihydroxy vitamin D3; Vitamin E; Insulin; Glucose uptake; Adipocytes; Protein kinase C **55**, 175

Dyslipidemia; 75 g oral glucose tolerance test; Initial insulin secretion; Impaired fasting glucose **55**, 159

Elderly; Type 2 diabetes; Quality of life; Carer stress **55**, 201

Epidemiology; Diabetes mellitus; Impaired glucose tolerance; Central obesity; Hypertension; Uzbekistan; Central Asia **55**, 19

Exercise; Walking; Physical activity **55**, 191

Fasting glucose; Diagnostic criteria; Diabetes; Screening; Asian populations; Oral glucose tolerance test **55**, 35

Fibrinogen; Visceral fat syndrome; Diabetic nephropathy; Thrombin–antithrombin III complex; Gender **55**, 139

Fibrocalculous pancreatopathy; *Reg*1α gene; *Reg*1β gene; Type 1 diabetes mellitus; Thai **55**, 105

GAD; β-Casein; Lymphoproliferation; Type 1 diabetes **55**, 237

Gender; Visceral fat syndrome; Diabetic nephropathy; Thrombin–antithrombin III complex; Fibrinogen **55**, 139

Glibenclamide; Acarbose; Insulin; Proinsulin; 24-h profiles **55**, 221

Glucose clamp; Insulin sensitivity; Oral glucose tolerance test; Homeostasis model assessment **55**, 229

Glucose uptake; 1α,25-Dihydroxy vitamin D3; Vitamin E; Insulin; Adipocytes; Protein kinase C **55**, 175

α-Glucosidase inhibitor; Voglibose; Acarbose; Postprandial hyperglycemia; Treatment of type 2 diabetes **55**, 99

75 g oral glucose tolerance test; Initial insulin secretion; Dyslipidemia; Impaired fasting glucose **55**, 159

Health economics; Cost burden; Type 1 diabetes; India **55**, 45

High-fat diet; Oral glucose tolerance test; Low-carbohydrate diet **55**, 61

HLA; *NeuroD*; Type 1 Diabetes; IDDM7; Residual beta-cell function **55**, 11

Homeostasis model assessment; Insulin sensitivity; Oral glucose tolerance test; Glucose clamp **55**, 229

Homocysteine; Cognitive deterioration; Diabetes mellitus **55**, 185

24-h profiles; Acarbose; Glibenclamide; Insulin; Proinsulin **55**, 221

Hydroxychloroquine; Oral hypoglycemic agent; Type 2 diabetes; Therapy **55**, 209

Hypertension; Diabetes mellitus; Impaired glucose tolerance; Central obesity; Epidemiology; Uzbekistan; Central Asia **55**, 19

IDDM7; *NeuroD*; Type 1 Diabetes; HLA; Residual beta-cell function **55**, 11

IGF-1; Insulin resistance; Ventricular myocyte; Cell shortening; Ca^{2+} transient **55**, 89

Imidapril; Diabetes mellitus; Captopril **55**, 113

Impaired fasting glucose; 75 g oral glucose tolerance test; Initial insulin secretion; Dyslipidemia **55**, 159

Impaired glucose tolerance; Diabetes mellitus; Central obesity; Hypertension; Epidemiology; Uzbekistan; Central Asia **55**, 19

India; Cost burden; Type 1 diabetes; Health economics **55**, 45

Initial insulin secretion; 75 g oral glucose tolerance test; Dyslipidemia; Impaired fasting glucose **55**, 159

Insulin; Acarbose; Glibenclamide; Proinsulin; 24-h profiles **55**, 221

Insulin; 1α,25-Dihydroxy vitamin D3; Vitamin E; Glucose uptake; Adipocytes; Protein kinase C **55**, 175

Insulin resistance; IGF-1; Ventricular myocyte; Cell shortening; Ca^{2+} transient **55**, 89

Insulin resistance; Type 2 diabetes mellitus; Soluble adhesion molecule; Insulin tolerance test; Multiple risk factors **55**, 131

Insulin sensitivity; Oral glucose tolerance test; Glucose clamp; Homeostasis model assessment **55**, 229

Insulin tolerance test; Type 2 diabetes mellitus; Soluble adhesion molecule; Insulin resistance; Multiple risk factors **55**, 131

JDS; Diabetes mellitus; Diagnosis; Classification **55**, 65

Ketoacidosis; Type 1 diabetes mellitus; Clinical manifestation; Onset; Childhood; Lithuania; Sweden **55**, 247

Lactoglobulin; Bovine serum albumin; Ovalbumin; Antibodies; Type 1 diabetes mellitus **55**, 1

Lithuania; Type 1 diabetes mellitus; Clinical manifestation; Onset; Ketoacidosis; Childhood; Sweden **55**, 247

Low-carbohydrate diet; Oral glucose tolerance test; High-fat diet **55**, 61

Lymphoproliferation; GAD; β-Casein; Type 1 diabetes **55**, 237

Middle East; Childhood diabetes mellitus; Arabs **55**, 29

Multiple risk factors; Type 2 diabetes mellitus; Soluble adhesion molecule; Insulin resistance; Insulin tolerance test **55**, 131

Native Canadians; Cardiovascular disease risk factors; Type 2 diabetes **55**, 165

NeuroD; Type 1 Diabetes; IDDM7; HLA; Residual beta-cell function **55**, 11

Onset; Type 1 diabetes mellitus; Clinical manifestation; Ketoacidosis; Childhood; Lithuania; Sweden **55**, 247

Oral glucose tolerance test; Diagnostic criteria; Diabetes; Fasting glucose; Screening; Asian populations **55**, 35

Oral glucose tolerance test; Insulin sensitivity; Glucose clamp; Homeostasis model assessment **55**, 229

Oral glucose tolerance test; Low-carbohydrate diet; High-fat diet **55**, 61

Oral hypoglycemic agent; Hydroxychloroquine; Type 2 diabetes; Therapy **55**, 209

Outcome; Post-renal transplant; Diabetes mellitus **55**, 123

Ovalbumin; Bovine serum albumin; Lactoglobulin; Antibodies; Type 1 diabetes mellitus **55**, 1

Physical activity; Walking; Exercise **55**, 191

Postprandial hyperglycemia; α-Glucosidase inhibitor; Voglibose; Acarbose; Treatment of type 2 diabetes **55**, 99

Post-renal transplant; Diabetes mellitus; Outcome **55**, 123

Proinsulin; Acarbose; Glibenclamide; Insulin; 24-h profiles **55**, 221

Protein kinase C; 1α,25-Dihydroxy vitamin D3; Vitamin E; Insulin; Glucose uptake; Adipocytes **55**, 175

Quality of life; Elderly; Type 2 diabetes; Carer stress **55**, 201

***Reg*1β gene**; *Reg*1α gene; Fibrocalculous pancreatopathy; Type 1 diabetes mellitus; Thai **55**, 105

***Reg*1α gene**; *Reg*1β gene; Fibrocalculous pancreatopathy; Type 1 diabetes mellitus; Thai **55**, 105

Residual beta-cell function; *NeuroD*; Type 1 Diabetes; IDDM7; HLA **55**, 11

Screening; Diabetic retinopathy; Digital image; Telemedicine **55**, 49

Screening; Diagnostic criteria; Diabetes; Fasting glucose; Asian populations; Oral glucose tolerance test **55**, 35

Soluble adhesion molecule; Type 2 diabetes mellitus; Insulin resistance; Insulin tolerance test; Multiple risk factors **55**, 131

Sweden; Type 1 diabetes mellitus; Clinical manifestation; Onset; Ketoacidosis; Childhood; Lithuania **55**, 247

Telemedicine; Diabetic retinopathy; Digital image; Screening **55**, 49

Thai; *Reg*1α gene; *Reg*1β gene; Fibrocalculous pancreatopathy; Type 1 diabetes mellitus **55**, 105

Therapy; Oral hypoglycemic agent; Hydroxychloroquine; Type 2 diabetes **55**, 209

Thrombin–antithrombin III complex; Visceral fat syndrome; Diabetic nephropathy; Fibrinogen; Gender **55**, 139

Treatment of type 2 diabetes; α-Glucosidase inhibitor; Voglibose; Acarbose; Postprandial hyperglycemia **55**, 99

Type 2 diabetes; Cardiovascular disease risk factors; Native Canadians **55**, 165

Type 1 diabetes; Cost burden; India; Health economics **55**, 45

Type 2 diabetes; Elderly; Quality of life; Carer stress **55**, 201

Type 1 diabetes; GAD; β-Casein; Lymphoproliferation **55**, 237

Type 1 diabetes mellitus; Bovine serum albumin; Lactoglobulin; Ovalbumin; Antibodies **55**, 1

Type 1 diabetes mellitus; Clinical manifestation; Onset; Ketoacidosis; Childhood; Lithuania; Sweden **55**, 247

Type 2 diabetes mellitus; Diabetic nephropathy; Diabetic retinopathy; Aldose reductase gene polymorphism **55**, 151

Type 1 diabetes mellitus; *Reg*1α gene; *Reg*1β gene; Fibrocalculous pancreatopathy; Thai **55**, 105

Type 2 diabetes mellitus; Soluble adhesion molecule; Insulin resistance; Insulin tolerance test; Multiple risk factors **55**, 131

Type 1 Diabetes; *NeuroD*; IDDM7; HLA; Residual beta-cell function **55**, 11

Type 2 diabetes; Oral hypoglycemic agent; Hydroxychloroquine; Therapy **55**, 209

Uzbekistan; Diabetes mellitus; Impaired glucose tolerance; Central obesity; Hypertension; Epidemiology; Central Asia **55**, 19

Ventricular myocyte; IGF-1; Insulin resistance; Cell shortening; Ca^{2+} transient **55**, 89

Visceral fat syndrome; Diabetic nephropathy; Thrombin–antithrombin III complex; Fibrinogen; Gender **55**, 139

Vitamin E; 1α,25-Dihydroxy vitamin D3; Insulin; Glucose uptake; Adipocytes; Protein kinase C **55**, 175

Voglibose; α-Glucosidase inhibitor; Acarbose; Postprandial hyperglycemia; Treatment of type 2 diabetes **55**, 99

Walking; Exercise; Physical activity **55**, 191